CoSci Med-Tech of Beijing led a $17 million Series A financing in JDP Therapeutics, a Pennsylvania company developing a novel injectable treatment for acute allergic reactions in the hospital market. JDP is ready to start a Phase III trial of JDP-205. The company believes the funding will be enough to bring JDP-205 all the way through FDA approval. CoSci will develop the drug in China and other parts of Asia, though the terms of the agreement were not disclosed.
